



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Methyltransferase like 3 gene (METTL3) Expression and Prognostic Impact in Acute Myeloid Leukaemia Patients

Thesis

*Submitted for partial fulfillment of M.D degree in Clinical and
Chemical Pathology*

Presented by

Reham Mohamed Nagy Mahmoud

*M.B.,B.Ch and M. Sc Clinical and Chemical Pathology
Faculty of Medicine- Ain Shams University*

Supervised by

Prof. Dr. Amal Abdel Hamid Mohamed

*Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Dr. Rasha Abdel Rahman El-Gamal

*Assistant Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Dr. Shaimaa Abdelmalik Pessar

*Assistant Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Dr. Shereen Abdel Monem Ibrahim

*Lecturer of Clinical and Chemical Pathology
Faculty of Medicine - in Shams University*

**Faculty of Medicine
Ain Shams University**

2021



التعبير الجيني لانزيم الميثيل ترانسفيراز و تأثيره على مآل

المرض في مرضى سرطان الدم الميلودى الحاد

رسالة

توطئة للحصول علي درجة الدكتوراه في الباثولوجيا الاكلينيكية

مقدمة من

الطبيبة / ريهام محمد ناجى محمود

بكالوريوس الطب و الجراحة، ماجستير الباثولوجيا الإكلينيكية

كلية الطب - جامعة عين شمس

تحت إشراف

أد/ امال عبد الحميد محمد

أستاذ الباثولوجيا الاكلينيكية

كلية الطب- جامعة عين شمس

د/ رشا عبد الرحمن الجمل

استاذ مساعد الباثولوجيا الاكلينيكية

كلية الطب- جامعة عين شمس

د/ شيماء عبد الملك بيصار

استاذ مساعد الباثولوجيا الاكلينيكية

كلية الطب- جامعة عين شمس

د/ شيرين عبد المنعم ابراهيم

مدرس الباثولوجيا الاكلينيكية

كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgement

*First and foremost thanks to **ALLAH**, the Most Merciful.*

*I wish to express my deep appreciation and sincere gratitude to **Prof. Dr. Amal Abdel Hamid Mohamed**, Professor of Clinical and Chemical Pathology, Ain Shams University, for her close supervision, valuable instructions, continuous help, patience, advices and guidance. She has generously devoted much of her time and effort for planning and supervision of this study. It was a great honor to me to work under his direct supervision.*

*I wish to express my great thanks and gratitude to **Dr. Rasha Abdel Rahman El-Gamal**, Assistant Professor of Clinical and Chemical Pathology, Ain Shams University, for her kind supervision, indispensable advice and great help in this work.*

*I wish to express my great thanks and gratitude to **Dr. Shaimaa Abdelmalik Pessar**, Assistant Professor of Clinical and Chemical Pathology, Ain Shams University, for her kind supervision, indispensable advice and great help in this work.*

*I wish to express my great thanks and gratitude to **Dr. Shereen Abdel Monem Ibrahim**, Lecturer of Clinical and Chemical Pathology, Ain Shams University, for her kind supervision, indispensable advice and great help in this work.*

Last and not least, I want to thank all my family, my colleagues,, for their valuable help and support.

Finally I would present all my appreciations to my patients without them, this work could not have been completed.

CONTENTS

Title	Page
• List of Abbreviations	I
• List of Table	IV
• List of Figures.....	VI
• List of Photo	VIII
• Introduction	1
• Aim of the work	4
• Review of literature.....	
Chapter (1): AML and cytogenetics with prognostic significance.....	5
Chapter (2): METTL3 in AML and its clinical significance.....	17
• Subject And Method.....	29
• Results	46
• Discussion.....	74
• Conclusion	86
• Recommendations	87
• Summary.....	88
• References	90
• الملخص العربي	102

LIST OF ABBREVIATIONS

Abb.	: Full term
2OG	: 2-oxoglutarat
ALKBH5	: Alkylated DNA repair protein alkB homolog 5
AML	: Acute myeloid leukemia
APL	: Acute promyelocytic leukemia
ASXL1	: Additional sex combs like 1
ATRA	: All-trans retinoic acid
BCL2	: B-cell lymphoma 2
BCOR	: BCL6 Corepressor
BM	: Bone marrow
CBC	: Complete blood count
cDNA	: Complementary deoxyribonucleic acid
CEBPA	: CCAAT/enhancer-binding protein alpha
circRNAs	: Circular RNAs
c-MYC	: Cellular myelocytomatosis
CNVs	: Copy number variations
CR	: Complete remission
CT	: Cycle threshold
DDX41	: DEAD-box polypeptide 41
DNA	: Deoxyribonucleic acid
DNMT3A	: DNA (cytosine-5) - methyltransferase 3A
EFS	: Event free survival
EGFR	: Epidermal growth factor receptor
EIciRNAs	: Exon-intron circRNAs
EZH2	: Enhancer of zeste homolog 2
FAB	: French-American-British classification
FISH	: Fluorescence In Situ Hybridization
FLT3	: Fetal liver tyrosine kinase-3
FTO	: Fat mass and obesity –associated protein
HGB	: Hemoglobin
HOTAIR	: Homeobox transcript antisense intergenic ribonucleic acid
HOX	: Homeobox
HS	: Highly significant

List of Abbreviations

Abb.	: Full term
HSC	: Hematopoietic stem cell
HSM	: Hepato-splenomegaly
IDH1	: Isocitrate dehydrogenase 1
IDH2	: Isocitrate dehydrogenase 2
inv	: Inversion
IPT	: Immunophenotyping
IQR	: Interquartile range
ITDs	: Internal tandem duplications
ITGA4	: Integrin Subunit Alpha 4
ITGAX	: Integrin Subunit Alpha X
k2-EDTA	: Dipotassium ethylene diamine tetra-acetic acid
lncRNAs	: long noncoding RNAs
LSC	: Leukemic stem cells
m6A	: Methyladenosine- N ⁶
MDS	: Myelodysplastic syndrome
METTL14	: Methyltransferase Like 14
METTL3	: Yltransferase Like 3
miRNAs	: Micornas
mL	: Mililiter
MLL	: Mixed lineage leukemia
mRNA	: Messenger ribonucleic acid
NAOX	: Nucleic acid oxygenase
ncRNAs	: Noncoding RNAs
NEAT1	: Nuclear Paraspeckle Assembly Transcript 1
NGS	: Next generation sequencing
NPM1	: Nuclophosmin-1
NRAS	: Neuroblastoma ras viral oncogene homolog
OS	: Overall survival
PB	: Peripheral blood
PHF6	: PHD Finger Protein 6
PLTs	: Platelets
PML-RARα	: Promyelocytic leukemia–retinoic acid receptor α
PTEN	: Phosphatase and Tensin Homolog
P-value	: Probability value
qRT-PCR	: Quantitative reverse transcription polymerase chain reaction

☞ List of Abbreviations

Abb.	: Full term
RARβ2	: Retinoic Acid Receptor Beta2
ROC	: Receiver operating characteristic
RTK	: Receptor tyrosine kinase
<i>RUNX 1</i>	: Runt-related transcription factor 1
S	: Significant
<i>SAH</i>	: S-adenosylhomocysteine
<i>SAM</i>	: S-adenosylmethionine
<i>SF3B1</i>	: Splicing Factor 3b Subunit 1
SFRSF2	: Splicing factor arginine/serine-rich 2
SNP	: Single-nucleotide polymorphism
SOX4	: SRY-box transcription factor 4
<i>SPI1</i>	: Spi-1 Proto-Oncogene
SPSS	: Statistical package for social science
STAG2	: Stromal Antigen 2
t	: Independent t-test
t	: Translocation
TERT	: Telomerase reverse transcriptase
TET2	: Ten-eleven translocation-2
TKD	: Tyrosine kinase domain
TLC	: Total leucocyte count
TP53	: Tumor protein P53
U2 snRNP	: U2 small nuclear ribonucleoprotein particle
U2AF1	: U2 small nuclear RNA auxiliary factor 1
μL	: Microliter
WHO	: World Health Organization
WTAP	: Wilms tumor 1-associating protein
X²	: Chi-square test
YTHDF1	: YTH N ⁶ -methyladenosine RNA binding protein1
YTHDF2	: YTH N ⁶ -methyladenosine RNA binding protein2
ZRSR2	: Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2

LIST OF TABLE

Table No	Subjects	Page
Table (1):	WHO classification of AML and related neoplasm	8
Table (2):	Lysis buffer mix	34
Table (3):	Genomic DNA elimination reaction components.....	38
Table (4):	Reverse-transcription master mix	38
Table (5):	Comparison between AML group vs. control group according to demographic and clinical data	47
Table (6):	Hematological parameters of AML cases at presentation	48
Table (7):	Comparison between AML cases vs. control group according to hematological parameters at time of diagnosis	49
Table (8):	IPT subtypes of the studied AML group.....	50
Table (9):	Cytogenetic (FISH) analysis of AML patients at time of diagnosis.....	52
Table (10):	Follow up- BM Blasts count	53
Table (11):	Comparison between AML cases vs. control group according to pretreatment METTL3 gene expression level	54
Table (12):	Statistical correlations between the known prognostic factors of AML and the METTL3 gene expression level at time of diagnosis	56
Table (13):	Comparison between the two AML subgroups (responder-non responder) according to their pretreatment METTL3 gene expression level	57

List of Table

Table No	Subjects	Page
Table (14):	Relation between AML subgroup with high normalized METTL3 expression and the other subgroup with low gene expression as regards their demographic and clinical data	60
Table (15):	Relation between AML subgroups as regards their hematological parameters:	62
Table (16):	Relation between AML subgroups as regards their IPT subtypes	63
Table (17):	Relation between AML subgroups as regards their cytogenetic (FISH) analysis at diagnosis	64
Table (18):	Comparison between pretreatment METTL3-based AML subgroups regarding of BM blasts in follow up samples from day 28 chemotherapy till the end of the 6th month of chemotherapy	65
Table (19):	METTL3 gene expression level post chemotherapy during follow up stages	68
Table (20):	Comparison between followed up patients with elevated gene levels versus patients with reduced gene levels (post treatment) regarding the frequency of elevated BM blast counts in follow up samples	69
Table (21):	Correlation of METTL3 gene expression level to blast count during follow up stages for assessment of early response to chemotherapy and maintenance of CR	71

LIST OF FIGURES

Figure No	Subjects	Page
Figure (1):	METTL3 (as well as the other complex components) are seen predominantly in nuclear speckles by immunofluorescence analyses, although m6A methyltransferase activity has been observed in both nuclear and cytoplasmic extracts.....	23
Figure (2):	It is clear that m6A plays important biological functions in plants, yeast, and mammals. For example, m6A modification via knockdown or deletion of the methyltransferase or demethylase affects plant growth, body mass and metabolism, synaptic function, circadian rhythm, early embryonic development, and stem cells differentiation.....	24
Figure (3):	Structural comparison between METTL3/METTL14 complex and EcoP15I in complex with its DNA substrate. PDB codes for METTL3/METTL14 and EcoP15I are 5IL1 and 4ZCF, respectively..	28
Figure (4):	Bar chart showing IPT subtypes of the studied AML patients.	50
Figure (5):	Pie chart shows distribution of patients according to pretreatment METTL3 gene expression level at diagnosis.	58
Figure (6):	Receiver-operating characteristic (ROC) curve detect the best cutoff value of METTL3 gene expression level at the time of diagnosis.....	59

Figure No	Subjects	Page
Figure (7):	Bar chart between AML with high METTL3 gene expression level vs. AML cases with low gene expression level according HSM.....	61
Figure (8):	Bar chart showing difference in BM blast counts during follow up stages in both METTL3- based AML subtypes.....	66
Figure (9):	Bar chart showing the follow up response in both AML subs groups with elevated and reduced gene expression level with treatment	70
Figure (10):	Scatter plot between METTL3 gene expression level during follow up and 2nd, 4th and 6th months BM blast counts %.....	72
Figure (11):	Kaplan-Meier survival curves to evaluate the impact of higher METTL3 expression on (EFS), yet The curve couldn't estimate statistical significance due to the few deaths number (only 3 cases). Interestingly, the curve revealed that all died cases were within the sub group of AML with high METTL3 expression level	73